Molecular Integration of Incretin and Glucocorticoid Action Reverses Immunometabolic Dysfunction and Obesity
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Molecular Integration of Incretin and Glucocorticoid Action Reverses Immunometabolic Dysfunction and Obesity. / Quarta, Carmelo; Clemmensen, Christoffer; Zhu, Zhimeng; Yang, Bin; Joseph, Sini S; Lutter, Dominik; Yi, Chun-Xia; Graf, Elisabeth; García-Cáceres, Cristina; Legutko, Beata; Fischer, Katrin; Brommage, Robert; Zizzari, Philippe; Franklin, Bernardo S; Krueger, Martin; Koch, Marco; Vettorazzi, Sabine; Li, Pengyun; Hofmann, Susanna M; Bakhti, Mostafa; Bastidas-Ponce, Aimée; Lickert, Heiko; Strom, Tim M; Gailus-Durner, Valerie; Bechmann, Ingo; Perez-Tilve, Diego; Tuckermann, Jan; Hrabě de Angelis, Martin; Sandoval, Darleen; Cota, Daniela; Latz, Eicke; Seeley, Randy J; Müller, Timo D; DiMarchi, Richard D; Finan, Brian; Tschöp, Matthias H.
I: Cell Metabolism, Bind 26, Nr. 4, 03.10.2017, s. 620-632.e6.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Molecular Integration of Incretin and Glucocorticoid Action Reverses Immunometabolic Dysfunction and Obesity
AU - Quarta, Carmelo
AU - Clemmensen, Christoffer
AU - Zhu, Zhimeng
AU - Yang, Bin
AU - Joseph, Sini S
AU - Lutter, Dominik
AU - Yi, Chun-Xia
AU - Graf, Elisabeth
AU - García-Cáceres, Cristina
AU - Legutko, Beata
AU - Fischer, Katrin
AU - Brommage, Robert
AU - Zizzari, Philippe
AU - Franklin, Bernardo S
AU - Krueger, Martin
AU - Koch, Marco
AU - Vettorazzi, Sabine
AU - Li, Pengyun
AU - Hofmann, Susanna M
AU - Bakhti, Mostafa
AU - Bastidas-Ponce, Aimée
AU - Lickert, Heiko
AU - Strom, Tim M
AU - Gailus-Durner, Valerie
AU - Bechmann, Ingo
AU - Perez-Tilve, Diego
AU - Tuckermann, Jan
AU - Hrabě de Angelis, Martin
AU - Sandoval, Darleen
AU - Cota, Daniela
AU - Latz, Eicke
AU - Seeley, Randy J
AU - Müller, Timo D
AU - DiMarchi, Richard D
AU - Finan, Brian
AU - Tschöp, Matthias H
N1 - Copyright © 2017 Elsevier Inc. All rights reserved.
PY - 2017/10/3
Y1 - 2017/10/3
N2 - Chronic inflammation has been proposed to contribute to the pathogenesis of diet-induced obesity. However, scarce therapeutic options are available to treat obesity and the associated immunometabolic complications. Glucocorticoids are routinely employed for the management of inflammatory diseases, but their pleiotropic nature leads to detrimental metabolic side effects. We developed a glucagon-like peptide-1 (GLP-1)-dexamethasone co-agonist in which GLP-1 selectively delivers dexamethasone to GLP-1 receptor-expressing cells. GLP-1-dexamethasone lowers body weight up to 25% in obese mice by targeting the hypothalamic control of feeding and by increasing energy expenditure. This strategy reverses hypothalamic and systemic inflammation while improving glucose tolerance and insulin sensitivity. The selective preference for GLP-1 receptor bypasses deleterious effects of dexamethasone on glucose handling, bone integrity, and hypothalamus-pituitary-adrenal axis activity. Thus, GLP-1-directed glucocorticoid pharmacology represents a safe and efficacious therapy option for diet-induced immunometabolic derangements and the resulting obesity.
AB - Chronic inflammation has been proposed to contribute to the pathogenesis of diet-induced obesity. However, scarce therapeutic options are available to treat obesity and the associated immunometabolic complications. Glucocorticoids are routinely employed for the management of inflammatory diseases, but their pleiotropic nature leads to detrimental metabolic side effects. We developed a glucagon-like peptide-1 (GLP-1)-dexamethasone co-agonist in which GLP-1 selectively delivers dexamethasone to GLP-1 receptor-expressing cells. GLP-1-dexamethasone lowers body weight up to 25% in obese mice by targeting the hypothalamic control of feeding and by increasing energy expenditure. This strategy reverses hypothalamic and systemic inflammation while improving glucose tolerance and insulin sensitivity. The selective preference for GLP-1 receptor bypasses deleterious effects of dexamethasone on glucose handling, bone integrity, and hypothalamus-pituitary-adrenal axis activity. Thus, GLP-1-directed glucocorticoid pharmacology represents a safe and efficacious therapy option for diet-induced immunometabolic derangements and the resulting obesity.
KW - Journal Article
U2 - 10.1016/j.cmet.2017.08.023
DO - 10.1016/j.cmet.2017.08.023
M3 - Journal article
C2 - 28943448
VL - 26
SP - 620-632.e6
JO - Cell Metabolism
JF - Cell Metabolism
SN - 1550-4131
IS - 4
ER -
ID: 186639408